Cellceutix Corporation (OTCBB: CTIX) is an emerging bio-pharmaceutical company developing small molecule therapies for cancer, autism and other diseases. Their lead drug, Kevetrin, an anti-cancer compound, has shown excellent results in preclinical testing of drug-resistant cancers (some of the most difficult of cancers). I believe that this Company is exciting enough to present to our readers. Some noteworthy points: Clinical trials are soon planned at Dana Farber/Harvard Cancer Center; the mechanism of action indicates they are activating, p53, the “guardian angel of the human genome”; the inventor of Kevetrin had previously been awarded the highest award at Lilly for his work on two blockbuster cancer drugs and believes this drug is better. Yet, Cellceutix has a market cap of about $40 million, potentially having plenty of upside.
As we promised in our introductory article on Cellceutix Corporation (OTCBB:CTIX) last week, we sat down and spent some time with Cellceutix Chief Executive Officer Leo Ehrlich to find out more about this up-and-coming biotechnology company.
Thank you for taking the time to speak with us, Leo. First off, can you tell us why you decided to form Cellceutix?
Ehrlich: Thank you for having me. My Mother had been diagnosed with stage four colon cancer and was receiving chemotherapy and experiencing difficulties due to the toxic treatments. I had already lost my father to cancer. I was discussing her condition with Dr. Krishna Menon, a dear friend of mine and a leading pharmaceutical researcher. I had great respect for Dr. Menon for his role in the development of Alimta and Gemzar, two of Eli Lilly and Company’s multi-billion dollar anti-cancer drugs. When we discussed his anti-cancer compounds in detail, I knew he was gifted in his capacity to understand cancer and its pharmacology. I then decided to invest my money with him at the helm, to find a better cancer treatment. It was an easy choice to form Cellceutix.
What drugs do you have on your pipeline?
Ehrlich: Our pipeline contains eight unique compounds. Kevetrin is ready to begin clinical trials as a compound to treat solid tumors. We have now turned our focus towards two other lead drug candidates. One is KM-133, an extremely promising drug for the treatment of psoriasis. The active moiety in KM-133 has already received FDA clearance, so we feel strongly that it will be eligible for a 505(b)(2) designation which would put it straight into late-stage clinical trials. We compared KM-133 and methotrexate, a common drug used today to treat psoriasis, and KM-133 clearly outperformed it. On our website,www.cellceutix.com, we have posted the images of mice with psoriasis that were tested. It’s quite astonishing how the psoriasis basically disappeared with our drug. The second compound, KM-391, is being developed as a treatment for the core issues of autism. We have conducted limited pre-clinical research which has provided great results thus far. Treatments for autism are extremely limited and current approved drug therapy only treats symptoms, not the core issues. We are targeting known physiologic conditions of the autistic brain, such as serotonin levels and brain plasticity, and hope to develop a first-in-class therapy.
The FDA has been criticized by some for not approving enough drugs. Does your anti-cancer compound, Kevetrin, have side effects which might prevent the drug from being approved?
Ehrlich: Well, I certainly can’t comment on whether the FDA approves enough drugs or not. I do believe, though, that we may have an advantage because Kevetrin is a totally new class of chemistry in medicine while many other drugs are merely reformulations of other drugs. A brand new entity to fight cancer either alone or as a combination therapy we believe is very desirable. As far as side effects, the profile built through pre-clinical research to date has shown no substantial side effects. Most importantly, Kevetrin has been shown to be non-genotoxic, meaning that it does not damage DNA. While it is impossible to discern if everything will translate to human trials, our toxicology studies give us confidence that there will not be any substantial side effects in clinical trials as well.
Why are you confident about Kevetrin?
Ehrlich: It is because of the p53 pathway. I could go on for quite some time about how important p53 is and how many companies have researched it over the last three decades trying to understand it and find a way to repair damaged or mutated p53 in cancer. It’s aptly dubbed name of “The Guardian Angel of the Human Genome” really says it all as it is a master regulator of cell cycles. Think about it this way: It is well documented that in at least half of all cancers, p53 is mutated or damaged and not performing its duty to regulate the life cycle of a cell; most importantly, not seeing to it that cancer cells are destroyed before they can continue to split and run rampant. We appear to have something that bridges the gap between damaged p53 and the massive amount of cancer patients it affects. Now, obviously, that is the short version. It is much more complex than that as there are different scenarios that define “wild” and “mutant” types of p53 and interactions with other proteins that delineate hundreds, if not thousands, of pathways that companies are researching. But, to the best of our knowledge, no one has collected the type of extremely promising data with their compound that we have. As biotechnology researchers, we – as well as all the other experts that have looked at Kevetrin’s data – have to be chronic cynics. That is what has driven us to test Kevetrin so extensively before heading into clinical trials. The data collected coupled with the responses that we have received from some of the brightest minds in oncology is what keeps our confidence level high at this point.
You announced that your Phase 1 is planned at Dana-Farber/Harvard Cancer Center. It’s unusual for a small cap company, especially for an OTCBB company, to be accepted for a trial there. Why do you believe they agreed to host your first clinical trial?
Ehrlich: The short version to that question is explained in my last answer with regards to a potential major breakthrough in cancer research. I cannot speak as to how many companies wish to sponsor their clinical trials at Dana-Farber, but as one of the world’s leading cancer research centers; I would assume that the number is very high. This allows them to be extremely selective. Believe me, we just went through the process to get approved and it is an arduous task as they are intensive in their research of the compound for a trial. Dana-Farber/Harvard Cancer Center sits at the pinnacle of cancer research and if a breakthrough is going to happen, it would seem logical that they want it to come through their center. They are well-funded and very prestigious. A Principal Investigator there does not want to be associated with a failure. So hosting a trial for any other reason than they like what they see and believe in the potential is the best answer that I can provide.
You have recently mentioned the Rb